N/A N=47 Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
Hypertension
Primary: Adverse Events — 47.8 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=53 Efficacy and Safety of Radiofrequency Renal Denervation in Drug Resistant Hypertension
Hypertension
Primary: Change in Office Systolic BP — -31.1 mmHg — p=<0.0001
Phase 1 N=19 RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157
Hypertension, Renal
Primary: Incidence of Major Adverse Events That Occurred Within 30 Days Post-procedure. — 0.0 percentage of participants
N/A N=106 Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
Uncontrolled Hypertension
Primary: Office Systolic Blood Pressure Reduction — -31.7; 0.9 mmHg
N/A N=126 Blood Pressure in Dialysis Patients
Hypertension · Renal Failure Chronic Requiring Hemodialysis · Blood Pressure
Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants
Phase 3 N=114 Irbesartan and Atenolol in Hypertensive Heart Disease
Hypertension
Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2
N/A N=337 SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System
Hypertension · Vascular Diseases · Cardiovascular Diseases
Primary: Acute and Chronic Safety by Evaluating Incidence of Major Adverse Events — 204; 130; 2; 1 Participants
Phase 3 N=947 Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
Atherosclerosis · Cardiovascular Diseases · Hypertension, Renovascular
Primary: Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent…
N/A N=146 Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
Hypertension
Primary: Change in Systolic and Diastolic Blood Pressure at Six (6) Months as Measured by Office-based Blood Pressure Assessment — -24.5; -10.3 mm Hg
N/A N=92 Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Systemic Arterial Hypertension · Hypertension Resistant to Conventional Therapy · Myocardial Infarction
Primary: Strokes, Either Fatal or Nonfatal — 24; 7 participants — p=0.19
Phase 4 N=24 Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension
Hypertension
Primary: Renal Oxygenation Changes After Chronic Treatment With Aliskiren or Hydrochlorothiazide — 20.5; 19.5; 19.5; 20.5 1/sec
N/A N=68 Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension
Renal Artery Stenosis · Hypertension, Renovascular
Primary: Primary Patency — 66 Subject-lesions — p=<.0001
N/A N=32 Mechanisms and Phenotypes of Hypertension in Patients in Chronic Hemodialysis
Arterial Hypertension · Hemodialysis
Primary: Cardiac Output — 3.9; 4.10; 4.6 L/min
N/A N=366 SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study
Hypertension · Vascular Diseases · Cardiovascular Diseases
Primary: Number of Participants With Major Adverse Events (MAE) Defined as a Composite of Events. — 0; 0 Participants
N/A N=70 Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation
Atrial Fibrillation · Hypertension
Primary: Proportion of Subjects in Each Arm That Experience Safety Composite Events — 1; 3 Participants — p=0.28
N/A N=51 Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
Hypertension
Primary: OBSERVATIONAL: Change (Mean Reduction) in Average 24-hour Ambulatory Systolic Blood Pressure (ASBP) Through 8 Weeks — -5.3; -8.5 mmHg
Phase 2 N=12 Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease
Hypertension · End Stage Renal Disease
Primary: Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period — -1.5; -3.7; -0.4 mm Hg
Phase 3 N=32 Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction
Hypertension With Renal Dysfunction
Primary: Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death) — 31.3; 0; 27.8; 43.8 Percentage of participants
Phase 4 N=16 Renal and Hormonal Effects of Pioglitazone
Diabetes · Hypertension
Primary: Effects of Pioglitazone on Renal Hemodynamics — 68.0; 62.4 ml/min/1.73m2
N/A N=202 The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis
Renal Artery Obstruction · Hypertension, Renal
Primary: Binary Restenosis Rate — 10.5 Percentage of lesions — p=< 0.0001
N/A N=50 Rapid Renal Sympathetic Denervation for Resistant Hypertension
Hypertension, Resistant to Conventional Therapy
Primary: Acute Procedural Safety — 4 percentage of participants
N/A N=17 A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
Hypertension · Plasma Renin Activity
Primary: Blood Pressure Control, as Defined as Office BP Measurement of <140 mmHg Systolic and <90 mmHg Diastolic — 3; 1 participants
N/A N=17 Renal Denervation for Management of Drug-Resistant Hypertension
Hypertension
Primary: Change in Systolic Blood Pressure From Baseline to 6 Months on 24-h Ambulatory Measurement (Follow-up Minus Baseline Measurement) — 0.7; -21.7 mmHg — p=0.018
N/A N=41 The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
Hyperparathyroidism
Primary: Parathyroid Hormone Following 1 Week of ACE Inhibitor Administration — 70.9; 32.5 pg/mL — p=0.049
Phase 4 N=23 Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients
Hypertension · Chronic Kidney Disease
Primary: The Change of Blood Pressure — -22.7; -5 mmHg
N/A N=68 Observational Study of the EnligHTN Renal Denervation System in Europe
Uncontrolled Hypertension
Primary: Mean Change in Office Systolic Blood Pressure at 6 Months — -13.6 mmHg
N/A N=14,986 Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany
Arterial Hypertension
Primary: Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP) — 11.8; 9.7; 9.9 percent change
N/A N=1,819 Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons
Hypertension
Primary: Change in Blood Pressure — -1; -2; -2; -2 mmHg
Phase 3 N=1,191 Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) — -31.37; -27.99; -30.77; -37.92 mmHg
Phase 4 N=860 Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
Hypertension · Diabetes Mellitus
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -28.82; -26.22 mmHg